MarketCap
Facebook
X
Telegram
NeuroMetrix Net Income | NURO
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income NeuroMetrix
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.81 M | -6.53 M | -4.42 M | -2.28 M | - | -3.77 M | 23.6 K | -12.9 M | -14.9 M | -9.19 M | -7.77 M | -8.02 M | -10 M | -9.98 M | -16.9 M | -11.9 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 23.6 K | -16.9 M | -8.42 M |
Quarterly Net Income NeuroMetrix
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.51 M | -1.49 M | -3.03 M | - | -1.77 M | -1.54 M | -1.57 M | - | -1.61 M | -1.16 M | -959 K | - | -687 K | -532 K | -59.8 K | - | -257 K | -852 K | -657 K | - | -1.4 M | -3.36 M | 2.05 M | - | 1.09 M | 574 K | 1.17 M | - | -3.51 M | -3.24 M | -3.23 M | - | -3.91 M | -4.1 M | -4.1 M | - | -3.2 M | -1.2 M | -2.07 M | - | -1.46 M | -2.17 M | -1.22 M | - | -716 K | -1.35 M | -2.25 M | - | -2.61 M | -2.77 M | -2.75 M | - | -2.43 M | -2.44 M | -2.7 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.05 M | -4.1 M | -1.69 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical instruments industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioLife Solutions
BLFS
|
-4.6 M | $ 36.38 | 0.54 % | $ 1.74 B |  USA |
 |
Ekso Bionics Holdings
EKSO
|
-50.3 M | - | - | $ 28.6 M | USA |
 |
Luminex Corporation
LMNX
|
15.2 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
-17.6 M | - | -9.52 % | $ 20.6 M | USA |
 |
CRH Medical Corporation
CRHM
|
-24.5 M | - | - | $ 282 M | USA |
 |
The Cooper Companies
COO
|
375 M | $ 71.17 | 0.3 % | $ 14.2 B | USA |
 |
Atrion Corporation
ATRI
|
19.4 M | - | - | $ 810 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
56.2 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
13.7 M | - | -1.18 % | $ 3.4 B | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
223 M | - | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
292 M | - | -0.02 % | $ 16.3 B | USA |
 |
Isoray
ISR
|
-103 M | - | 0.03 % | $ 108 M | USA |
 |
Merit Medical Systems
MMSI
|
128 M | $ 90.49 | 1.06 % | $ 5.35 B | USA |
 |
AtriCure
ATRC
|
-11.4 M | $ 48.54 | 2.28 % | $ 2.32 B | USA |
 |
Nephros
NEPH
|
1.19 M | $ 4.55 | 5.57 % | $ 48.3 M | USA |
 |
Haemonetics Corporation
HAE
|
97.3 M | $ 103.96 | 0.03 % | $ 4.9 B | USA |
 |
Predictive Oncology
POAI
|
-233 M | - | - | $ 31.1 M | USA |
 |
Glaukos Corporation
GKOS
|
-188 M | $ 179.87 | 0.74 % | $ 10.3 B | USA |
 |
Harvard Bioscience
HBIO
|
-56.7 M | $ 7.93 | 0.38 % | $ 352 M | USA |
 |
AngioDynamics
ANGO
|
-36.7 M | $ 15.85 | 0.44 % | $ 658 M | USA |
 |
ICU Medical
ICUI
|
732 K | $ 175.1 | 0.43 % | $ 4.31 B | USA |
 |
InfuSystem Holdings
INFU
|
6.63 M | $ 12.04 | 0.12 % | $ 249 M | USA |
 |
iRhythm Technologies
IRTC
|
-45 M | $ 120.25 | 3.37 % | $ 3.85 B | USA |
 |
STERIS plc
STE
|
782 M | $ 233.78 | 0.35 % | $ 23 B | USA |
 |
Pro-Dex
PDEX
|
8.98 M | $ 62.56 | 1.6 % | $ 206 B | USA |
 |
Baxter International
BAX
|
-957 M | $ 26.13 | 0.81 % | $ 13.4 B | USA |
 |
Repligen Corporation
RGEN
|
48.9 M | $ 176.27 | 0.96 % | $ 9.91 M | USA |
 |
Pulse Biosciences
PLSE
|
-72.8 M | $ 47.57 | 0.04 % | $ 3.21 B | USA |
 |
ResMed
RMD
|
1.52 B | $ 240.33 | 1.94 % | $ 35 B | USA |
 |
Intuitive Surgical
ISRG
|
2.86 B | $ 372.6 | 1.51 % | $ 133 B | USA |
 |
electroCore
ECOR
|
-14 M | $ 9.63 | 1.54 % | $ 81.7 K | USA |
 |
DENTSPLY SIRONA
XRAY
|
-598 M | $ 11.12 | 0.72 % | $ 2.22 B | USA |
 |
Milestone Scientific
MLSS
|
-5.72 M | $ 0.5 | 0.36 % | $ 41 M | USA |
 |
Alcon
ALC
|
980 M | $ 72.01 | 0.07 % | $ 35.5 B |  Schweiz |
 |
West Pharmaceutical Services
WST
|
494 M | $ 337.47 | 0.11 % | $ 24.4 B | USA |
 |
Envista Holdings Corporation
NVST
|
47 M | $ 27.13 | 0.02 % | $ 4.56 B | USA |
 |
Masimo Corporation
MASI
|
-305 M | - | - | $ 9.59 B | USA |
 |
Microbot Medical
MBOT
|
-13.1 M | $ 1.48 | 0.33 % | $ 67.8 M |  Israel |
 |
STAAR Surgical Company
STAA
|
-80.4 M | $ 22.11 | 0.09 % | $ 1.1 B | USA |
 |
Stereotaxis
STXS
|
-21.6 M | $ 1.45 | 0.34 % | $ 132 M | USA |
 |
Repro Med Systems
KRMD
|
-2.64 M | $ 3.23 | 0.94 % | $ 149 M | USA |
 |
OraSure Technologies
OSUR
|
-68.7 M | $ 3.6 | 0.13 % | $ 265 M | USA |
 |
Teleflex Incorporated
TFX
|
-906 M | $ 139.67 | 1.42 % | $ 6.23 B | USA |
 |
LeMaitre Vascular
LMAT
|
57.7 M | $ 80.45 | 0.99 % | $ 1.82 B | USA |
 |
Becton, Dickinson and Company
BDX
|
1.68 B | $ 189.52 | 0.74 % | $ 54.5 B | USA |
 |
Retractable Technologies
RVP
|
-12.6 M | $ 0.73 | 1.14 % | $ 21.9 M | USA |
 |
Utah Medical Products
UTMD
|
2.56 M | $ 72.77 | 1.35 % | $ 236 M | USA |